PROCEDURE

SEGOVA Program consists of several separate procedures integrated in a common project aimed to support, increase or create elements necessary for normal gonadal function.
The first letters of the SEGOVA abbreviation in fact represent the specific procedures:

S – Stem cell therapy
Cell therapy which uses autologous stem cells – cells obtained from the patients’ own body. The aim is to create new or incite existing non-differentiated gonadal stem cells – which are to be developed into new oocytes or sperm cells and the hormone-producing cells.

E – Energy mitochondrial boosting
Stem cell therapy is correcting mitochondrial function in existing cells However, boosting mitochondrial energy production in gonadal cells with a specific physical exercise regime – HIIT (High Intensity Interval Training) is a combination of highly intensive, intermittent, specific anaerobic exercise.

G – Growth factor PLPR therapy
Growth factors are essential mediators in gonadal control mechanisms. These growth factors are obtained from the patient’s own blood and used to treat gonadal tissue. They act by controlling the creation and growth of eggs and the surrounding cells responsible for hormone production. In recent years, ovarian revitalization methods have been applied worldwide in order to improve the hormonal and reproductive conditions of the patient and thus their quality of life. PLRP is a separated part of the whole blood where the high platelet level is concentrated, but with growth factors of 3 to 5 times the plasma concentration. Growth factors are found in the granules and they play an important role in cell proliferation, chemotaxis, promotion of angiogenesis and differentiation of mesenchymal and other types of cells.

OVA – Ovarian in Vitro Activation
The production of eggs – oogenesis, is dependent on proper genetic control. Hippo the signaling pathway is essential for maintaining optimum organ size. It contains several negative growth regulators. The AKT the signaling pathway has a key role in the initiation of follicle growth. The ovarian in vitro activation represents the autologous genetic treatment of the gonadal tissue in order to restore both reproductive and endocrine functions of the ovary.

The age-related decline in testosterone along with the associated symptoms has been referred to as male menopause or the andropause. Partial androgen deficiency and the decline in testosterone seen in ageing men has clinical implications. Along with the decline in testosterone, some men experience symptoms that include: fatigue, weakness, depression, sexual dysfunction. Standard medical therapy today – Testosterone replacement is connected with potential risks and side effects.

SEGOVA Program for men follows the standard set of SEGOVA procedures and includes the standard follow up program.

• The sample of 93 patients, aged 31 – 60 , (average value 46,64)  diagnosed with infertility completed the Segova program and participated In one year long follow up.
• The sample of 93 patinets had sonographic and hormone level (FSH, LH, E2, PG, AMH) follow up throughout  the course  of one year since the procedure.
• The study was conducted at the Specialized OBGYN hospital Jevremova Belgrade, Saint James Hospital in Malta, Remedica Hospital in Skopje, from 2015 to 2019.
• All the patients have undergone preparatory laboratory analysis and completed the questionnaires about menstrual cycles, parity, presence of POF-a diagnosis in family history, education level and possible sources of stress prior to amenorrhea. Questionnaires concerning life quality were also completed.  

From the total number of patients, 7 patients were pregnant (3 spontaneous and 4 IVF pregnancies) + 2 pregnancies with additional reproductive technologies.

From 9 pregnancies in total – 3 missed pregnancies, 1 chromosomopathy, and 4 succesfull pregnancies ( one twin pregnancy + one pregnancy with additional reproductive technologies currently In progress = total of 5 babies were born)